Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.74 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.74 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.73 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.59 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30418194 | 1.00 | GABRA1 (0.74) | GABRA1GABRB2GABRB1GABRA3MEN1 | |
| SCHEMBL5309810 | 0.91 | NR4A2 (0.72) | GABRA1GABRB2GABRB1GABRA3MEN1 | |
| SCHEMBL27774066 | 0.90 | GABRA1 (0.60) | GABRA1GABRB2GABRB1GABRA3MEN1 | |
| SCHEMBL30906938 | 0.90 | GABRA1 (0.63) | GABRA1GABRB2GABRB1GABRA3MEN1 | |
| SCHEMBL30906939 | 0.90 | GABRA1 (0.63) | GABRA1GABRB2GABRB1GABRA3MEN1 | |
| SCHEMBL7294152 | 0.90 | GABRA1 (0.63) | GABRA1GABRB2GABRB1GABRA3MEN1 | |
| SCHEMBL28289133 | 0.88 | GABRA1 (0.65) | GABRA1GABRB2GABRB1GABRA3MEN1 | |
| SCHEMBL30417619 | 0.86 | GABRA1 (0.78) | GABRA1GABRB2GABRB1GABRA3MEN1 | |
| SCHEMBL7284420 | 0.86 | GABRA1 (0.78) | GABRA1GABRB2GABRB1GABRA3MEN1 | |
| SCHEMBL7291769 | 0.85 | GABRA1 (1.00) | GABRA1GABRB2GABRB1GABRA3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615523-A1 | COMPOUNDS AND THEIR USE | KING'S COLLEGE LONDON (GB) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024100095-A1 | COMPOUNDS AND THEIR USE | KING’S COLLEGE LONDON (GB) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024100095-A1 | COMPOUNDS AND THEIR USE | KING’S COLLEGE LONDON (GB) | 2024-05-16 | — | — | WO | disclosed |
| CN-109651247-A | A kind of green high-efficient synthetic method of carbostyril compound | 云南民族大学 | 2019-04-19 | — | — | CN | disclosed |
| US-8889706-B2 | Soluble mTOR complexes and modulators thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889706-B2 | Soluble mTOR complexes and modulators thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889706-B2 | Soluble mTOR complexes and modulators thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-11-18 | — | — | US | disclosed |
| EP-2350053-B1 | Modulators of MTOR Complexes | WHITEHEAD BIOMEDICAL INST (US) | 2013-12-11 | — | — | EP | disclosed |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8394818-B2 | Soluble mTOR complexes and modulators thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394818-B2 | Soluble mTOR complexes and modulators thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394818-B2 | Soluble mTOR complexes and modulators thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2010044885-A2 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | MTOR, RICTOR, RPTOR | GABRA1 3089/4885GABRB2 2786/4885GABRB1 2799/4885 |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | MTOR, RICTOR, RPTOR | GABRA1 3089/4885GABRB2 2786/4885GABRB1 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.